142,957 members

Skip to content. | Skip to navigation

News

Additional evidence needed to assess histology-independent cancer drugs

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

Additional evidence needed to assess histology-independent cancer drugs

Additional evidence collection will be needed to assess histology-independent cancer drugs - a new kind of cancer treatment - a paper published and co-authored by NICE staff has said.

The paper, published in the British Medical Journal, looks at how histology-independent cancer drugs might be appraised by organisations such as NICE. Reliable evidence is needed to inform NICE recommendations and the paper explores how histology-independent cancer drugs present a challenge for its technology appraisal process.